578 related articles for article (PubMed ID: 12728159)
41. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
ZuWallack AR; ZuWallack RL
Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
[TBL] [Abstract][Full Text] [Related]
42. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.
Casaburi R; Briggs DD; Donohue JF; Serby CW; Menjoge SS; Witek TJ
Chest; 2000 Nov; 118(5):1294-302. PubMed ID: 11083677
[TBL] [Abstract][Full Text] [Related]
43. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
44. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
Bateman ED; Tashkin D; Siafakas N; Dahl R; Towse L; Massey D; Pavia D; Zhong NS
Respir Med; 2010 Oct; 104(10):1460-72. PubMed ID: 20620037
[TBL] [Abstract][Full Text] [Related]
45. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Cope S; Zhang J; Williams J; Jansen JP
BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
[TBL] [Abstract][Full Text] [Related]
47. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
Vincken W; van Noord JA; Greefhorst AP; Bantje TA; Kesten S; Korducki L; Cornelissen PJ;
Eur Respir J; 2002 Feb; 19(2):209-16. PubMed ID: 11871363
[TBL] [Abstract][Full Text] [Related]
48. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
[TBL] [Abstract][Full Text] [Related]
49. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
[TBL] [Abstract][Full Text] [Related]
50. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne L; Irvin-Sellers MJ; White J
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009552. PubMed ID: 26391969
[TBL] [Abstract][Full Text] [Related]
51. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
52. Tolerance to bronchodilating effects of salmeterol in COPD.
Donohue JF; Menjoge S; Kesten S
Respir Med; 2003 Sep; 97(9):1014-20. PubMed ID: 14509555
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
54. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.
Anzueto A; Niewoehner DE; Leimer I; Rühmkorf F; Celli BR; Decramer M; Tashkin DP
Respir Med; 2013 Dec; 107(12):1912-22. PubMed ID: 23969305
[TBL] [Abstract][Full Text] [Related]
55. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
56. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
57. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).
Vogelmeier CF; Asijee GM; Kupas K; Beeh KM
Adv Ther; 2015 Jun; 32(6):537-47. PubMed ID: 26100349
[TBL] [Abstract][Full Text] [Related]
58. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
59. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
60. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]